真性巨大脾动脉瘤临床特征与管理的系统综述
该系统综述纳入2004至2018年文献及作者经验共92例真性巨大脾动脉瘤(GSAA,>5 cm),平均年龄56.1±17.3岁,73%有症状,34%破裂,总死亡率12.5%。手术(53.4%)较腔内治疗(44.3%)并发症更低(P = .041),再干预和死亡率相当;手术仍为标准治疗,腔内治疗可用于高危患者。
要点
- GSAA破裂率34%,总死亡率12.5%,需及时诊断处理。
- 手术并发症低于腔内治疗(P = .041),再干预和死亡率相当。
- 腔内治疗可作为高危患者替代,尤其瘤体<10 cm或起源异常者。
核心结论
- GSAA罕见但破裂风险高,及时诊断和管理对获得满意结局至关重要。
- 手术仍是GSAA的标准治疗,腔内干预是高危患者的可行替代。
研究设计与样本
- 系统综述纳入2004至2018年文献及作者个人经验,共回顾92例GSAA病例。
- 分析GSAA的解剖和临床特征、治疗方式及结局(再干预、并发症和死亡率)。
主要发现
- GSAA平均发病年龄56.1±17.3岁,无性别倾向,73%就诊时有症状。
- 腹痛是>50%病例的就诊症状,34%破裂,总死亡率12.5%。
- 破裂组常表现为消化道出血或血流动力学崩溃。
- 动脉瘤在脾动脉上分布几乎均匀,8.7%合并动静脉瘘形成。
- 88例接受手术(53.4%)、腔内(44.3%)或联合(2.3%)治疗,最常见术式为动脉瘤切除联合脾切除伴或不伴附加切除。
关键数值与推荐
- GSAA定义为>5 cm的真性脾动脉瘤。
- 手术并发症低于腔内治疗(P = .041),再干预和死亡率相当。
- 腔内干预可用于高危患者,尤其瘤体<10 cm或起源异常者。
临床怎么用
- 对>5 cm的真性脾动脉瘤应警惕破裂风险,及时诊断并积极处理。
- 手术切除(常联合脾切除)是标准治疗方式。
- 高危患者可考虑腔内治疗,尤其瘤体<10 cm或起源异常时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: True giant splenic artery aneurysms (GSAAs) >5 cm are rare and present unique therapeutic challenges. The aim of this study was to evaluate the anatomic and clinical characteristics of these lesions and the current surgical and endovascular techniques available for their treatment. METHODS: A systematic review of the literature from 2004 to 2018 and the personal experience of the authors with management of GSAAs are presented. A total of 92 GSAA cases were reviewed. Analyses were performed on anatomic and clinical features and management modalities and outcomes of GSAA, including reintervention, morbidity, and mortality. RESULTS: GSAA presented at a mean age of 56.1 ± 17.3 years, with no sex predilection; 73% were symptomatic at presentation. Abdominal pain was the presenting symptom in >50% of cases; 34% percent were ruptured, with an overall mortality rate of 12.5%. This group often presented with gastrointestinal bleeding or hemodynamic collapse. The aneurysms were almost evenly distributed across the splenic artery and were not uncommonly associated with arteriovenous fistula formation (8.7%). There were 88 patients who had surgical (53.4%), endovascular (44.3%), or combination (2.3%) therapy. The most commonly performed procedure was aneurysmectomy and splenectomy with or without additional resection. Overall, surgical treatment had a lower morbidity (P = .041) than endovascular therapy and comparable reintervention and mortality rates. CONCLUSIONS: GSAAs are uncommon vascular lesions, with distinct clinical features and aneurysm characteristics. Considering their high risk of rupture, timely diagnosis and management are essential to attain a satisfactory outcome. Surgery remains the standard treatment of these lesions. Endovascular intervention is a viable alternative in high-risk patients, particularly those with lesions <10 cm or with anomalous origin.
引用
- Hamid HKS, Suliman AEA, Piffaretti G, et al. A systematic review on clinical features and management of true giant splenic artery aneurysms. J Vasc Surg. 2019. PMID: 31727456. doi:10.1016/j.jvs.2019.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。